ACTIVE TB AFTER THE USE OF TOCILIZUMAB FOR COVID-19 INFECTION
Sign Up to like & getrecommendations! Published in 2021 at "Chest"
DOI: 10.1016/j.chest.2021.07.295
Abstract: TOPIC: Chest Infections TYPE: Fellow Case Reports INTRODUCTION: Tocilizumab is a humanized anti-IL-6 receptor antibody and inhibits the binding of IL-6 to its receptors, associated with Th17 and Th22 cell differentiation which is critical for… read more here.
Keywords: use tocilizumab; covid infection; tuberculosis; tocilizumab ... See more keywords
Rationale and evidence on the use of tocilizumab in COVID-19: a systematic review
Sign Up to like & getrecommendations! Published in 2020 at "Pulmonology"
DOI: 10.1016/j.pulmoe.2020.07.003
Abstract: Abstract Background Tocilizumab is an IL-6 receptor-blocking agent proposed for the treatment of severe COVID-19. The aim of this systematic review was to describe the rationale for the use of tocilizumab for the treatment of… read more here.
Keywords: use tocilizumab; covid; systematic review; evidence ... See more keywords
253: Use of Tocilizumab in the Treatment of COVID-19
Sign Up to like & getrecommendations! Published in 2020 at "Critical Care Medicine"
DOI: 10.1097/01.ccm.0000726900.86356.9c
Abstract: INTRODUCTION: Severely ill patients with COVID-19 pneumonia have been found to have an extensive cytokine mediated inflammatory response This has been demonstrated by elevated pro-inflammatory markers, including interleukin 6 (IL-6) Tocilizumab is an IL-6 antagonist… read more here.
Keywords: use tocilizumab; administration; treatment; received tocilizumab ... See more keywords
THU0599 Evaluation of efficacy and safety of canakinumab in japanese patients with systemic juvenile idiopathic arthritis in phase iii clinical trial, composed predominantly of patients with prior use of tocilizumab
Sign Up to like & getrecommendations! Published in 2018 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2018-eular.2464
Abstract: Background Systemic juvenile idiopathic arthritis (SJIA) is a distinct form of juvenile idiopathic arthritis (JIA), accounting for approximately 4% to 17% of JIA1. In Japan, a higher frequency of SJIA, 41.7% of JIA2 has been… read more here.
Keywords: use tocilizumab; juvenile idiopathic; pts achieved; idiopathic arthritis ... See more keywords
Targeting IL-6 in COVID-19. Response to: ‘Rational use of tocilizumab in COVID-19’ by Jain and Sharma
Sign Up to like & getrecommendations! Published in 2020 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2020-218627
Abstract: Dear Editor, Siddharth and Sharma1 suggest caution in using interleukin-6 (IL-6) receptor blocking agents, namely tocilizumab, in the treatment of patients with COVID-19 infection, particularly those requiring invasive mechanical ventilation because of the increased risk… read more here.
Keywords: use tocilizumab; covid response; targeting covid; tocilizumab ... See more keywords